August 21, 2019
Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) was found ineligible for the price maintenance premium (PMP) , but all five immune checkpoint inhibitors including it will see price rises in Japan’s ad-hoc re-pricing associated with the consumption tax hike in October...read more